Nasenspray Glucagon: A Technical Pros and Cons Analysis
Abstract: Nasenspray glucagon, a novel intranasal peptide formulation, offers rapid hypoglycemia reversal without injection. Technically, its absorption via nasal mucosa bypasses first-pass metabolism, enhancing bioavailability versus injectables, but stability challenges require specialized excipients. Market trends show a 12.3% CAGR for peptide therapeutics (2024-2030), with Eli Lilly’s Baqsimi leading brand share (68%). Key pros include needle-free administration and faster onset (11 min vs. 15 min for IM); cons involve higher cost ($280 vs. $150) and limited shelf-life (24 months vs. 36 months). Regulatory approvals (FDA, EMA) and GMP-certified peptide synthesis are critical for quality. For selection, prioritize lyophilized powder stability and cold-chain logistics (2-8°C). Industry data indicates 89% patient preference for nasal spray, driving future R&D.